European muscle MRI study in limb girdle muscular dystrophy type R1/2A (LGMDR1/LGMD2A).
CAPN3 mutations
LGMDR1/LGMD2A
Mercuri score
Muscle MRI
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
19
07
2019
accepted:
10
09
2019
revised:
09
09
2019
pubmed:
27
9
2019
medline:
23
10
2020
entrez:
27
9
2019
Statut:
ppublish
Résumé
Limb girdle muscular dystrophy type R1/2A (LGMDR1/LGMD2A) is a progressive myopathy caused by deficiency of calpain 3, a calcium-dependent cysteine protease of skeletal muscle, and it represents the most frequent type of LGMD worldwide. In the last few years, muscle magnetic resonance imaging (MRI) has been proposed as a tool for identifying patterns of muscular involvement in genetic disorders and as a biomarker of disease progression in muscle diseases. In this study, 57 molecularly confirmed LGMDR1 patients from a European cohort (age range 7-78 years) underwent muscle MRI and a global evaluation of functional status (Gardner-Medwin and Walton score and ability to raise the arms). We confirmed a specific pattern of fatty substitution involving predominantly the hip adductors and hamstrings in lower limbs. Spine extensors were more severely affected than spine rotators, in agreement with higher incidence of lordosis than scoliosis in LGMDR1. Hierarchical clustering of lower limb MRI scores showed that involvement of anterior thigh muscles discriminates between classes of disease progression. Severity of muscle fatty substitution was significantly correlated with CAPN3 mutations: in particular, patients with no or one "null" alleles showed a milder involvement, compared to patients with two null alleles (i.e., predicting absence of calpain-3 protein). Expectedly, fat infiltration scores strongly correlated with functional measures. The "pseudocollagen" sign (central areas of sparing in some muscle) was associated with longer and more severe disease course. We conclude that skeletal muscle MRI represents a useful tool in the diagnostic workup and clinical management of LGMDR1.
Sections du résumé
BACKGROUND
BACKGROUND
Limb girdle muscular dystrophy type R1/2A (LGMDR1/LGMD2A) is a progressive myopathy caused by deficiency of calpain 3, a calcium-dependent cysteine protease of skeletal muscle, and it represents the most frequent type of LGMD worldwide. In the last few years, muscle magnetic resonance imaging (MRI) has been proposed as a tool for identifying patterns of muscular involvement in genetic disorders and as a biomarker of disease progression in muscle diseases. In this study, 57 molecularly confirmed LGMDR1 patients from a European cohort (age range 7-78 years) underwent muscle MRI and a global evaluation of functional status (Gardner-Medwin and Walton score and ability to raise the arms).
RESULTS
RESULTS
We confirmed a specific pattern of fatty substitution involving predominantly the hip adductors and hamstrings in lower limbs. Spine extensors were more severely affected than spine rotators, in agreement with higher incidence of lordosis than scoliosis in LGMDR1. Hierarchical clustering of lower limb MRI scores showed that involvement of anterior thigh muscles discriminates between classes of disease progression. Severity of muscle fatty substitution was significantly correlated with CAPN3 mutations: in particular, patients with no or one "null" alleles showed a milder involvement, compared to patients with two null alleles (i.e., predicting absence of calpain-3 protein). Expectedly, fat infiltration scores strongly correlated with functional measures. The "pseudocollagen" sign (central areas of sparing in some muscle) was associated with longer and more severe disease course.
CONCLUSIONS
CONCLUSIONS
We conclude that skeletal muscle MRI represents a useful tool in the diagnostic workup and clinical management of LGMDR1.
Identifiants
pubmed: 31555977
doi: 10.1007/s00415-019-09539-y
pii: 10.1007/s00415-019-09539-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
45-56Références
Hum Mutat. 2000 Mar;15(3):295
pubmed: 10679950
Cell. 1995 Apr 7;81(1):27-40
pubmed: 7720071
Am J Med Genet A. 2004 Mar 1;125A(2):152-6
pubmed: 14981715
Eur J Neurol. 2007 Jul;14(7):819-22
pubmed: 17594342
Hum Mutat. 2010 Sep;31(9):E1658-69
pubmed: 20635405
Neuromuscul Disord. 2018 Aug;28(8):702-710
pubmed: 30055862
Neuromuscul Disord. 2012 Oct 1;22 Suppl 2:S68-84
pubmed: 22980770
Neuromuscul Disord. 2005 Mar;15(3):218-24
pubmed: 15725583
Neuromuscul Disord. 2011 Nov;21(11):791-9
pubmed: 21803581
Neuromuscul Disord. 2012 Oct 1;22 Suppl 2:S100-6
pubmed: 22980760
Brain. 2005 Apr;128(Pt 4):732-42
pubmed: 15689361
Sci Rep. 2017 Nov 22;7(1):16060
pubmed: 29167533
Nucleic Acids Res. 2009 May;37(9):e67
pubmed: 19339519
J Neuromuscul Dis. 2016 Mar 3;3(1):1-28
pubmed: 27854210
Am J Hum Genet. 1999 Jun;64(6):1524-40
pubmed: 10330340
J Cell Biol. 2000 Dec 25;151(7):1583-90
pubmed: 11134085
Muscle Nerve. 2018 Oct;58(4):536-541
pubmed: 29797799
Handb Clin Neurol. 2011;101:97-110
pubmed: 21496626
Ann Neurol. 1997 Aug;42(2):222-9
pubmed: 9266733
Brain. 1996 Feb;119 ( Pt 1):295-308
pubmed: 8624690
Eur J Hum Genet. 2002 Dec;10(12):825-32
pubmed: 12461690
Neuromuscul Disord. 2005 Apr;15(4):303-10
pubmed: 15792870
Brain. 1998 Sep;121 ( Pt 9):1735-47
pubmed: 9762961
Am J Hum Genet. 1997 May;60(5):1128-38
pubmed: 9150160
Clin Genet. 2006 May;69(5):444-9
pubmed: 16650086
J Neurol Neurosurg Psychiatry. 2018 Jan;89(1):72-77
pubmed: 28889091
J Neurol Neurosurg Psychiatry. 2018 Oct;89(10):1071-1081
pubmed: 29735511
Eur Radiol. 2016 Mar;26(3):693-705
pubmed: 26115655
J Magn Reson Imaging. 2007 Feb;25(2):433-40
pubmed: 17260395
Genet Test Mol Biomarkers. 2015 Nov;19(11):637-40
pubmed: 26484845
Clin Neuropathol. 2014 May-Jun;33(3):179-85
pubmed: 24618072
Ann Clin Transl Neurol. 2016 Mar 04;3(4):248-65
pubmed: 27081656
PLoS One. 2014 Feb 28;9(2):e90377
pubmed: 24587344
Brain. 2016 Aug;139(Pt 8):2154-63
pubmed: 27259757
J Inherit Metab Dis. 2012 Sep;35(5):837-45
pubmed: 22290025
Croat Med J. 2005 Aug;46(4):657-63
pubmed: 16100770